Combination Enoxaparin and Abciximab During Percutaneous Coronary Intervention: A New Standard of Care?
Evidence from randomized trials supports the administration of platelet glycoprotein (GP) IIb/IIIa blockade both to patients undergoing percutaneous coronary intervention (PCI) and those presenting with non-ST elevation acute coronary syndromes (ACSs). Similarly, the low molecular weight heparin (LMWH), enoxaparin, has demonstrated superior efficacy when compared with unfractionated heparin (UFH) in the treatment of patients with non-ST elevation ACS. Algorithms for seamless integration of pharmacotherpy through the course of hospitalization for patients who present with ACS and who require PCI will likely combine therapy with enoxaparin and platelet GP IIb/IIIa blockade (abciximab). Our preliminary experience with combination enoxaparin and abciximab as adjunctive pharmacotherapy for PCI suggests that this strategy is safe and effective and may offer advantages over a conventional strategy, which employs UFH.
Kereiakes
DJ
Lindner Center for Research and Education, 2123 Auburn Avenue, Suite 424, Cincinnati, OH 45219, USA. lindner@fuse.net
Grines
C
Fry
E
Esente
A
Barr
L
Matthai
W
Shimshak
T
Broderick
T
Cohen
M